Central nervous system teratoma is a rare extragonadal germ cell tumor of the brain or spinal cord composed of tissues from multiple germ layers. It belongs to the central nervous system germ cell tumor spectrum, including the nongerminomatous germ cell tumor group when immature, malignant, or mixed components are present. Clinical manifestations are driven by tumor location, with pineal, suprasellar, ventricular, brain, and spinal lesions producing obstructive hydrocephalus, visual or endocrine symptoms, and local neurologic compression. Management is histology- and extent-dependent: complete resection is central for mature teratoma, while chemotherapy, radiation therapy, and second-look surgery are used for mixed, immature, malignant, residual, or growing-teratoma-syndrome contexts.
Ask a research question about Central Nervous System Teratoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Central Nervous System Teratoma
creation_date: "2026-05-09T13:23:37Z"
updated_date: "2026-05-09T23:23:14Z"
synonyms:
- CNS teratoma
- intracranial teratoma
- spinal teratoma
- teratoma of the central nervous system
description: >-
Central nervous system teratoma is a rare extragonadal germ cell tumor of the
brain or spinal cord composed of tissues from multiple germ layers. It belongs
to the central nervous system germ cell tumor spectrum, including the
nongerminomatous germ cell tumor group when immature, malignant, or mixed
components are present. Clinical manifestations are driven by tumor location,
with pineal, suprasellar, ventricular, brain, and spinal lesions producing
obstructive hydrocephalus, visual or endocrine symptoms, and local neurologic
compression. Management is histology- and extent-dependent: complete resection
is central for mature teratoma, while chemotherapy, radiation therapy, and
second-look surgery are used for mixed, immature, malignant, residual, or
growing-teratoma-syndrome contexts.
categories:
- Central Nervous System Neoplasm
- Germ Cell Neoplasm
- Pediatric Brain Tumor
- Extragonadal Teratoma
parents:
- teratoma
- extragonadal teratoma
- central nervous system nongerminomatous germ cell tumor
disease_term:
preferred_term: central nervous system teratoma
term:
id: MONDO:0002718
label: central nervous system teratoma
definitions:
- name: CNS teratoma literature definition
definition_type: CASE_DEFINITION
scope: Literature definition for intracranial and spinal CNS teratoma.
description: >-
A rare CNS neoplasm containing tissues from germ layers, diagnosed by
histopathology and classified by the maturity and malignant transformation of
teratomatous elements.
evidence:
- reference: PMID:25150764
reference_title: "Management of central nervous system teratoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Central nervous system (CNS) teratomas are very rare neoplasms that contain
tissues derived from all three germ cell layers (endoderm, mesoderm, and
ectoderm).
explanation: >-
This retrospective CNS teratoma review directly defines the disease by
rarity, CNS location, and multilineage germ-layer tissue composition.
- reference: PMID:21150046
reference_title: "Teratomas in central nervous system: a clinico-morphological study with review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
BACKGROUND: Cranio-spinal axis teratomas are rare. This subset is
interesting because symptoms can be varied, depending on the location.
Histopathology is diagnostic; most of the lesions are benign. Rarely,
malignancy develops in any of the somatic components.
explanation: >-
This craniospinal series supports CNS/spinal localization,
histopathologic diagnosis, and the benign-to-malignant histologic range.
has_subtypes:
- name: Mature Teratoma
description: >-
Teratoma composed predominantly of mature, well-differentiated tissues.
Complete resection is the central treatment goal when anatomically feasible.
evidence:
- reference: PMID:21150046
reference_title: "Teratomas in central nervous system: a clinico-morphological study with review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
RESULTS: A total of 14 tumors were diagnosed as teratomas. Of these, 11
were mature cystic teratomas; and 1 case each, of teratoma with malignant
transformation, terato-carcinoma and mixed germ cell tumor (immature
teratoma with germinoma).
explanation: >-
The case series directly includes mature cystic teratoma as the dominant
CNS teratoma subtype.
- name: Immature Teratoma
description: >-
Teratoma containing immature tissue. Immature histology is clinically
important because it is associated with poorer prognosis and with mixed
nongerminomatous germ cell tumor treatment pathways.
evidence:
- reference: PMID:36995447
reference_title: "Impact of tumor markers on diagnosis, treatment and prognosis in CNS germ cell tumors: correlations with clinical practice and histopathology."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Immature teratoma demonstrated unfavorable prognosis independent of tumor
marker status, with 56% 5-year overall survival; however, co-existent
germinoma components indicated a more favorable prognosis.
explanation: >-
This histopathology-verified CNS GCT cohort supports immature teratoma as
a clinically meaningful high-risk histologic subtype.
- name: Teratoma With Malignant Transformation
description: >-
Teratoma with malignant somatic-type features or transformation within
teratomatous tissue. This subtype is rare and requires management according
to the transformed malignant component and feasibility of resection.
evidence:
- reference: PMID:21150046
reference_title: "Teratomas in central nervous system: a clinico-morphological study with review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
RESULTS: A total of 14 tumors were diagnosed as teratomas. Of these, 11
were mature cystic teratomas; and 1 case each, of teratoma with malignant
transformation, terato-carcinoma and mixed germ cell tumor (immature
teratoma with germinoma).
explanation: >-
This series documents malignant transformation as one observed CNS
teratoma subtype.
- name: Intracranial Growing Teratoma Syndrome
description: >-
Treatment-associated enlargement of a teratomatous mass during or after
therapy for CNS germ cell tumor despite normalization of tumor markers.
evidence:
- reference: PMID:32297094
reference_title: "Intracranial growing teratoma syndrome (iGTS): an international case series and review of the literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
PURPOSE: Intracranial growing teratoma syndrome (iGTS) is a rare phenomenon
of paradoxical growth of a germ cell tumor (GCT) during treatment despite
normalization of tumor markers.
explanation: >-
This multi-institution series defines iGTS and supports modeling it as a
clinically important teratoma-related treatment-course subtype.
prevalence:
- population: CNS tumor literature
notes: CNS teratoma is consistently described as very rare.
evidence:
- reference: PMID:25150764
reference_title: "Management of central nervous system teratoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Central nervous system (CNS) teratomas are very rare neoplasms that contain
tissues derived from all three germ cell layers (endoderm, mesoderm, and
ectoderm).
explanation: The abstract directly supports rarity of CNS teratoma.
progression:
- phase: Pediatric and young adult presentation
age_range: Childhood to young adulthood
notes: CNS germ cell tumors most commonly arise in the second decade of life.
evidence:
- reference: PMID:36521378
reference_title: "Primary central nervous system germ cell tumors in children and young adults: A review of controversies in diagnostic and treatment approach."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Primary central nervous system (CNS) germ cell tumors (GCT) are a rare
heterogenous group of cancers, arising most commonly in the second decade
of life.
explanation: >-
This CNS GCT review supports the typical age distribution for the broader
disease family that includes CNS teratoma.
- phase: Spinal compressive presentation
notes: >-
Spinal mature teratomas can produce progressive local compressive symptoms,
including sensory symptoms and back pain, before resection.
evidence:
- reference: PMID:38357074
reference_title: "Mature Teratoma at the Lumbar Spinal Cord: A Case Report and Literature Review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
It has the ability to grow independently and cause compressive symptoms
when found in this rare location.
explanation: >-
This spinal mature teratoma case report and review supports a compressive
spinal presentation pattern.
- phase: Growing teratoma syndrome during treatment
notes: >-
A subset of CNS germ cell tumor patients develop paradoxical growth of a
teratomatous component during treatment despite tumor marker normalization,
often early after diagnosis.
evidence:
- reference: PMID:32297094
reference_title: "Intracranial growing teratoma syndrome (iGTS): an international case series and review of the literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
iGTS occurred at a median of 2 months (range 0.5-32) from diagnosis, in
the majority of patients.
explanation: >-
This supports the early treatment-course timing of intracranial growing
teratoma syndrome.
pathophysiology:
- name: Primordial Germ Cell Developmental Origin
description: >-
CNS teratomas arise within the CNS germ cell tumor spectrum, where the
prevailing developmental model is that primordial germ cells or germ-cell-like
precursors become ectopically located in midline CNS structures and then form
tumors with embryonic differentiation potential.
cell_types:
- preferred_term: primordial germ cell
term:
id: CL:0000670
label: primordial germ cell
locations:
- preferred_term: central nervous system
term:
id: UBERON:0001017
label: central nervous system
biological_processes:
- preferred_term: germ cell migration
modifier: ABNORMAL
term:
id: GO:0008354
label: germ cell migration
- preferred_term: germ cell development
modifier: ABNORMAL
term:
id: GO:0007281
label: germ cell development
evidence:
- reference: PMID:34671804
reference_title: "The Japan Society for Neuro-Oncology guideline on the diagnosis and treatment of central nervous system germ cell tumors."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
In line with the hypothesis that the primordial germ cell is the
cell-of-origin, histopathological examinations for this pathology involve a
diverse range of components mirroring the embryogenic developmental
dimensions.
explanation: >-
The CNS GCT guideline supports the primordial germ cell origin hypothesis
and the developmental diversity of histologic components.
downstream:
- target: Multilineage Teratomatous Differentiation
description: Ectopic germ-cell-derived tumor cells retain multilineage differentiation potential.
- name: Multilineage Teratomatous Differentiation
description: >-
Teratomatous tumor cells differentiate into tissue derivatives from
ectodermal, mesodermal, and endodermal lineages, producing mature, immature,
mixed, or transformed histologic patterns.
cell_types:
- preferred_term: primordial germ cell
term:
id: CL:0000670
label: primordial germ cell
biological_processes:
- preferred_term: cell differentiation
modifier: ABNORMAL
term:
id: GO:0030154
label: cell differentiation
evidence:
- reference: PMID:25150764
reference_title: "Management of central nervous system teratoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Central nervous system (CNS) teratomas are very rare neoplasms that contain
tissues derived from all three germ cell layers (endoderm, mesoderm, and
ectoderm).
explanation: >-
This directly supports teratomatous multilineage differentiation from all
three germ layers.
- reference: PMID:21150046
reference_title: "Teratomas in central nervous system: a clinico-morphological study with review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Morphologically, a variety of tissue derivatives were seen in the cases.
explanation: >-
This clinico-morphological series supports varied tissue derivatives in CNS
teratoma specimens.
downstream:
- target: Expansile CNS Mass Effect
description: Differentiated teratomatous tissue forms a space-occupying CNS mass.
- name: CNS Germ Cell Tumor Copy-Number Alteration
description: >-
CNS teratomas and related CNS germ cell tumors can show copy-number
alterations. A recent malignant-feature growing teratoma syndrome case
identified DMRT1 loss and 12p gain, supporting a copy-number alteration
mechanism in at least some aggressive teratomatous lesions.
genes:
- preferred_term: DMRT1
term:
id: hgnc:2934
label: DMRT1
biological_processes:
- preferred_term: chromosome organization
modifier: ABNORMAL
term:
id: GO:0051276
label: chromosome organization
evidence:
- reference: PMID:38668041
reference_title: "Successful Multimodal Treatment of Intracranial Growing Teratoma Syndrome with Malignant Features."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
Methylation classifier analysis confirmed the diagnosis of teratoma, and
DMRT1 loss and 12p gain were identified by copy number variation analysis,
potentially elucidating the cause of growth and malignant transformation
of the teratoma.
explanation: >-
This is single-case molecular evidence, so it partially supports
copy-number alteration as a mechanism for aggressive CNS teratomatous
growth and transformation.
downstream:
- target: Expansile CNS Mass Effect
description: Copy-number altered teratomatous components can contribute to growth and malignant transformation.
- name: Expansile CNS Mass Effect
description: >-
Growth of teratomatous tissue within restricted CNS spaces compresses neural
structures and obstructs cerebrospinal fluid pathways, especially in pineal,
suprasellar, ventricular, and spinal locations.
locations:
- preferred_term: brain
term:
id: UBERON:0000955
label: brain
- preferred_term: pineal gland
term:
id: UBERON:0001905
label: pineal body
- preferred_term: spinal cord
term:
id: UBERON:0002240
label: spinal cord
biological_processes:
- preferred_term: cell population proliferation
modifier: INCREASED
term:
id: GO:0008283
label: cell population proliferation
evidence:
- reference: PMID:35821434
reference_title: "Pediatric pineal region tumors: institutional experience of surgical managements with posterior interhemispheric transtentorial approach."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Hydrocephalus caused the main presenting symptoms and was noted in 74
patients.
explanation: >-
This pediatric pineal region surgical series supports obstructive
hydrocephalus as a major mass-effect consequence in a cohort containing
pineal teratomas.
- reference: PMID:39035740
reference_title: "Primary central nervous system germ cell tumors in Central America and the Caribbean Region: an AHOPCA 20-year experience."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Presenting symptoms were headaches (n = 24, 50%), visual disturbances (n =
17, 35.4%), vomiting (n = 12, 25%), nausea (n = 8, 16.7%), and diabetes
insipidus (n = 7, 14.6%).
explanation: >-
This pediatric CNS GCT cohort supports the mass-effect and midline-region
symptom pattern used for CNS teratoma phenotypes.
downstream:
- target: Obstructive Hydrocephalus and Neurologic-Endocrine Deficits
description: Tumor mass effect blocks CSF pathways or compresses visual, endocrine, and neural structures.
- name: Growing Teratoma Syndrome
description: >-
During treatment of CNS germ cell tumor, mature or immature teratomatous
components may continue to enlarge despite normalization of AFP or beta-hCG,
requiring surgical management.
biological_processes:
- preferred_term: cell population proliferation
modifier: INCREASED
term:
id: GO:0008283
label: cell population proliferation
evidence:
- reference: PMID:32297094
reference_title: "Intracranial growing teratoma syndrome (iGTS): an international case series and review of the literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
PURPOSE: Intracranial growing teratoma syndrome (iGTS) is a rare phenomenon
of paradoxical growth of a germ cell tumor (GCT) during treatment despite
normalization of tumor markers.
explanation: >-
This defines the treatment-related growth phenomenon and supports it as a
mechanism affecting clinical course.
downstream:
- target: Expansile CNS Mass Effect
description: Enlarging teratomatous tissue can worsen compressive CNS manifestations despite marker normalization.
- target: Second-Look Surgery for Growing Teratoma Syndrome
description: Continued enlargement despite normalized tumor markers creates a rationale for surgical resection.
histopathology:
- name: Teratomatous Germ-Layer Tissue Derivatives
finding_term:
preferred_term: Teratoma
term:
id: NCIT:C3403
label: Teratoma
diagnostic: true
description: >-
Mature or immature tissue derivatives from multiple germ layers are the
diagnostic microscopic basis for CNS teratoma.
evidence:
- reference: PMID:25150764
reference_title: "Management of central nervous system teratoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Central nervous system (CNS) teratomas are very rare neoplasms that contain
tissues derived from all three germ cell layers (endoderm, mesoderm, and
ectoderm).
explanation: >-
This supports germ-layer tissue composition as the histopathologic basis
for the diagnosis.
- reference: PMID:21150046
reference_title: "Teratomas in central nervous system: a clinico-morphological study with review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Histopathology is diagnostic; most of the lesions are benign. Rarely,
malignancy develops in any of the somatic components.
explanation: >-
This supports diagnostic reliance on histopathology and acknowledges
malignant transformation within somatic components.
genetic:
- name: DMRT1 Loss and Chromosome 12p Gain
association: Somatic copy-number alteration in a malignant-feature iGTS case
gene_term:
preferred_term: DMRT1
term:
id: hgnc:2934
label: DMRT1
notes: >-
Reported in a single intracranial growing teratoma syndrome case with
malignant features; not established as a universal CNS teratoma driver.
evidence:
- reference: PMID:38668041
reference_title: "Successful Multimodal Treatment of Intracranial Growing Teratoma Syndrome with Malignant Features."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
Methylation classifier analysis confirmed the diagnosis of teratoma, and
DMRT1 loss and 12p gain were identified by copy number variation analysis,
potentially elucidating the cause of growth and malignant transformation
of the teratoma.
explanation: >-
Single-case molecular profiling supports this as a possible alteration in
aggressive teratomatous disease but not a generalizable causal rule.
phenotypes:
- category: Neurological
name: Headache
frequency: FREQUENT
description: >-
Headache is a common presenting symptom in pediatric CNS germ cell tumor
cohorts and likely reflects mass effect or raised intracranial pressure.
phenotype_term:
preferred_term: Headache
term:
id: HP:0002315
label: Headache
evidence:
- reference: PMID:39035740
reference_title: "Primary central nervous system germ cell tumors in Central America and the Caribbean Region: an AHOPCA 20-year experience."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Presenting symptoms were headaches (n = 24, 50%), visual disturbances (n =
17, 35.4%), vomiting (n = 12, 25%), nausea (n = 8, 16.7%), and diabetes
insipidus (n = 7, 14.6%).
explanation: This CNS GCT cohort reports headache in 50% of patients.
- category: Neurological
name: Hydrocephalus
frequency: VERY_FREQUENT
description: >-
Pineal-region teratomas can obstruct cerebrospinal fluid flow and produce
hydrocephalus.
phenotype_term:
preferred_term: Hydrocephalus
term:
id: HP:0000238
label: Hydrocephalus
evidence:
- reference: PMID:35821434
reference_title: "Pediatric pineal region tumors: institutional experience of surgical managements with posterior interhemispheric transtentorial approach."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Hydrocephalus caused the main presenting symptoms and was noted in 74
patients.
explanation: >-
This surgical series supports hydrocephalus as a very common presentation
of pineal-region tumors, including 18 teratomas among the GCT cases.
- category: Ophthalmologic
name: Visual Impairment
frequency: FREQUENT
description: >-
Visual symptoms may arise from pineal, suprasellar, intracranial pressure,
or other midline CNS involvement.
phenotype_term:
preferred_term: Visual impairment
term:
id: HP:0000505
label: Visual impairment
evidence:
- reference: PMID:39035740
reference_title: "Primary central nervous system germ cell tumors in Central America and the Caribbean Region: an AHOPCA 20-year experience."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Presenting symptoms were headaches (n = 24, 50%), visual disturbances (n =
17, 35.4%), vomiting (n = 12, 25%), nausea (n = 8, 16.7%), and diabetes
insipidus (n = 7, 14.6%).
explanation: This CNS GCT cohort reports visual disturbance in 35.4% of patients.
- category: Ophthalmologic
name: Parinaud Syndrome
frequency: OCCASIONAL
description: >-
Parinaud syndrome or Parinaud sign can occur with pineal-region tumors
affecting the dorsal midbrain, including teratomas within pineal-region germ
cell tumor cohorts.
phenotype_term:
preferred_term: Parinaud syndrome
evidence:
- reference: PMID:35821434
reference_title: "Pediatric pineal region tumors: institutional experience of surgical managements with posterior interhemispheric transtentorial approach."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
Parinaud's sign was noted in 24 patients, of which 16 were transient.
explanation: >-
This pediatric pineal-region tumor series reports Parinaud sign in 24
patients and included 18 teratomas among the germ cell tumors; support is
partial because the frequency is not teratoma-specific.
- category: Gastrointestinal
name: Vomiting
frequency: OCCASIONAL
description: >-
Vomiting can accompany raised intracranial pressure, obstructive
hydrocephalus, or mass effect.
phenotype_term:
preferred_term: Vomiting
term:
id: HP:0002013
label: Vomiting
evidence:
- reference: PMID:39035740
reference_title: "Primary central nervous system germ cell tumors in Central America and the Caribbean Region: an AHOPCA 20-year experience."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Presenting symptoms were headaches (n = 24, 50%), visual disturbances (n =
17, 35.4%), vomiting (n = 12, 25%), nausea (n = 8, 16.7%), and diabetes
insipidus (n = 7, 14.6%).
explanation: This CNS GCT cohort reports vomiting in 25% of patients.
- category: Gastrointestinal
name: Nausea
frequency: OCCASIONAL
description: >-
Nausea may accompany raised intracranial pressure or tumor-related vomiting.
phenotype_term:
preferred_term: Nausea
term:
id: HP:0002018
label: Nausea
evidence:
- reference: PMID:39035740
reference_title: "Primary central nervous system germ cell tumors in Central America and the Caribbean Region: an AHOPCA 20-year experience."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Presenting symptoms were headaches (n = 24, 50%), visual disturbances (n =
17, 35.4%), vomiting (n = 12, 25%), nausea (n = 8, 16.7%), and diabetes
insipidus (n = 7, 14.6%).
explanation: This CNS GCT cohort reports nausea in 16.7% of patients.
- category: Endocrine
name: Diabetes Insipidus
frequency: OCCASIONAL
description: >-
Diabetes insipidus can occur with suprasellar or hypothalamic-pituitary axis
involvement by CNS germ cell tumors.
phenotype_term:
preferred_term: Diabetes insipidus
term:
id: HP:0000873
label: Diabetes insipidus
evidence:
- reference: PMID:39035740
reference_title: "Primary central nervous system germ cell tumors in Central America and the Caribbean Region: an AHOPCA 20-year experience."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Presenting symptoms were headaches (n = 24, 50%), visual disturbances (n =
17, 35.4%), vomiting (n = 12, 25%), nausea (n = 8, 16.7%), and diabetes
insipidus (n = 7, 14.6%).
explanation: This CNS GCT cohort reports diabetes insipidus in 14.6% of patients.
- category: Endocrine
name: Precocious Puberty
frequency: VERY_RARE
description: >-
Precocious puberty is an uncommon presentation in nongerminomatous CNS germ
cell tumors and may reflect beta-hCG secretion in some tumor components.
phenotype_term:
preferred_term: Precocious puberty
term:
id: HP:0000826
label: Precocious puberty
evidence:
- reference: PMID:39035740
reference_title: "Primary central nervous system germ cell tumors in Central America and the Caribbean Region: an AHOPCA 20-year experience."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Two patients with NGGCT presented with precocious puberty.
explanation: >-
This supports rare precocious puberty in nongerminomatous CNS germ cell
tumors.
diagnosis:
- name: Histopathologic Diagnosis
description: >-
Histopathology is the definitive basis for CNS teratoma diagnosis and
distinguishes mature, immature, mixed, and malignant-transformed components.
evidence:
- reference: PMID:21150046
reference_title: "Teratomas in central nervous system: a clinico-morphological study with review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Histopathology is diagnostic; most of the lesions are benign. Rarely,
malignancy develops in any of the somatic components.
explanation: >-
This directly supports histopathology as diagnostic for CNS teratoma and
its malignant transformation spectrum.
- name: Serum and CSF Tumor Marker Assessment
markers: HCG, AFP
description: >-
Serum and cerebrospinal fluid human chorionic gonadotropin and
alpha-fetoprotein are used in CNS germ cell tumor diagnosis and risk
stratification, but immature teratoma can complicate marker interpretation.
evidence:
- reference: PMID:36995447
reference_title: "Impact of tumor markers on diagnosis, treatment and prognosis in CNS germ cell tumors: correlations with clinical practice and histopathology."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Tumor markers in CNS germ cell tumors (GCTs) include human chorionic
gonadotropin (HCG) and alpha fetoprotein (AFP), which have significant
diagnostic implications, as elevation of either one leads to clinical
diagnosis of non-germinomatous GCTs without histopathological confirmation,
justifying intensified chemotherapy and irradiation.
explanation: >-
This supports the diagnostic importance of HCG and AFP in CNS GCTs.
- reference: PMID:36995447
reference_title: "Impact of tumor markers on diagnosis, treatment and prognosis in CNS germ cell tumors: correlations with clinical practice and histopathology."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
AFP was often elevated in GCTs without a yolk sac tumor component,
especially immature teratoma.
explanation: >-
This supports the important diagnostic nuance that AFP elevation can occur
in immature teratoma without yolk sac tumor.
- name: Pineal Region Surgical Evaluation
description: >-
MRI-defined pineal region masses often require hydrocephalus management,
biopsy, or resection depending on tumor marker and histologic context.
evidence:
- reference: PMID:35821434
reference_title: "Pediatric pineal region tumors: institutional experience of surgical managements with posterior interhemispheric transtentorial approach."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Nine patients had ETV together with endoscopic biopsy.
explanation: >-
This supports combined CSF diversion and biopsy as part of pineal-region
diagnostic management in selected cases.
treatments:
- name: Maximal Safe Resection
description: >-
Surgical resection is central for diagnosis, relief of mass effect, and
durable control of mature teratoma when complete removal is feasible.
treatment_term:
preferred_term: surgical procedure
term:
id: MAXO:0000004
label: surgical procedure
evidence:
- reference: PMID:21150046
reference_title: "Teratomas in central nervous system: a clinico-morphological study with review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Excision was curative or provided symptomatic relief in most cases;
terato-carcinoma and mixed germ cell tumor patients needed adjuvant
radiotherapy.
explanation: >-
This CNS teratoma series supports excision as curative or symptom-relieving
in most cases.
- name: Chemotherapy
description: >-
Chemotherapy is used in CNS germ cell tumor care, particularly for immature,
malignant, mixed, residual, or nongerminomatous components rather than for
completely resected mature teratoma alone.
treatment_term:
preferred_term: chemotherapy
term:
id: MAXO:0000647
label: chemotherapy
evidence:
- reference: PMID:34671804
reference_title: "The Japan Society for Neuro-Oncology guideline on the diagnosis and treatment of central nervous system germ cell tumors."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Chemotherapy and radiotherapy are the mainstays of treatment, with surgery
having a limited role for diagnosis and debulking of residual tissue after
treatment.
explanation: >-
This guideline abstract supports chemotherapy as a main treatment modality
for CNS germ cell tumors.
- name: Platinum-Etoposide Chemotherapy Context
description: >-
Cisplatin, carboplatin, ifosfamide, and etoposide are common agents in CNS
germ cell tumor chemotherapy backbones, used in risk-adapted protocols for
nongerminomatous disease.
treatment_term:
preferred_term: chemotherapy
term:
id: MAXO:0000647
label: chemotherapy
therapeutic_agent:
- preferred_term: cisplatin
term:
id: CHEBI:27899
label: cisplatin
- preferred_term: carboplatin
term:
id: CHEBI:31355
label: carboplatin
- preferred_term: etoposide
term:
id: CHEBI:4911
label: etoposide
- preferred_term: ifosfamide
term:
id: CHEBI:5864
label: ifosfamide
evidence:
- reference: clinicaltrials:NCT01424839
reference_title: "SIOP CNS GCT II: Prospective Trial for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Intracranial Germ Cell Tumors"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The IMPs on this trial are Carboplatin, Cisplatin, Ifosfamide and
Etoposide (as approved by German competent authority).
explanation: >-
This clinical trial record directly names the platinum, ifosfamide, and
etoposide agents used in CNS germ cell tumor treatment protocols.
- name: High-Dose Chemotherapy With Peripheral Stem Cell Transplantation
description: >-
High-dose chemotherapy with peripheral stem cell transplantation is studied
as an escalation strategy in newly diagnosed intracranial germ cell tumors
when response before radiotherapy is incomplete or high-risk therapy is
needed. This is partial evidence for CNS teratoma because it applies most
directly to nongerminomatous or mixed CNS germ cell tumor contexts.
treatment_term:
preferred_term: hematopoietic stem cell transplantation
term:
id: MAXO:0000747
label: hematopoietic stem cell transplantation
evidence:
- reference: clinicaltrials:NCT00047320
reference_title: "A Phase II Study To Assess The Ability Of Neoadjuvant Chemotherapy Plus/Minus Second Look Surgery To Eliminate All Measurable Disease Prior To Radiotherapy For NGGCT"
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
PURPOSE: This Phase II trial is studying how well neoadjuvant chemotherapy
with or without surgery and with or without high dose chemotherapy and
peripheral stem cell transplantation, can increase response rates prior to
radiation therapy and increase progression free and overall surviving
patients with newly diagnosed intracranial germ cell tumors.
explanation: >-
This supports high-dose chemotherapy with peripheral stem cell
transplantation as a studied escalation approach in intracranial germ cell
tumors, with partial applicability to CNS teratoma-containing NGGCTs.
- name: Radiation Therapy
description: >-
Radiation therapy is used in multimodality CNS germ cell tumor treatment and
as adjuvant therapy for teratocarcinoma or mixed germ cell tumor in older CNS
teratoma series.
treatment_term:
preferred_term: radiation therapy
term:
id: MAXO:0000014
label: radiation therapy
evidence:
- reference: PMID:34671804
reference_title: "The Japan Society for Neuro-Oncology guideline on the diagnosis and treatment of central nervous system germ cell tumors."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Chemotherapy and radiotherapy are the mainstays of treatment, with surgery
having a limited role for diagnosis and debulking of residual tissue after
treatment.
explanation: >-
This guideline abstract supports radiotherapy as a main modality in CNS
germ cell tumor treatment.
- reference: PMID:21150046
reference_title: "Teratomas in central nervous system: a clinico-morphological study with review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Excision was curative or provided symptomatic relief in most cases;
terato-carcinoma and mixed germ cell tumor patients needed adjuvant
radiotherapy.
explanation: >-
This directly supports adjuvant radiotherapy for malignant or mixed CNS
teratomatous disease contexts.
- name: Endoscopic Third Ventriculostomy or CSF Diversion
description: >-
CSF diversion can be needed before tumor resection when a pineal or
ventricular CNS teratoma causes obstructive hydrocephalus.
treatment_term:
preferred_term: surgical procedure
term:
id: MAXO:0000004
label: surgical procedure
target_phenotypes:
- preferred_term: Hydrocephalus
term:
id: HP:0000238
label: Hydrocephalus
evidence:
- reference: PMID:35821434
reference_title: "Pediatric pineal region tumors: institutional experience of surgical managements with posterior interhemispheric transtentorial approach."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
It was treated prior to the craniotomy for tumor resection with endoscopic
third ventriculostomy (ETV) in 33, external ventricular drainage in 26, and
precraniotomy shunt in 15.
explanation: >-
This supports pre-resection CSF diversion for hydrocephalus in pineal-region
tumors, including teratomas.
- name: Second-Look Surgery for Growing Teratoma Syndrome
description: >-
Surgical resection is the key treatment for intracranial growing teratoma
syndrome or residual enlarging teratomatous mass after treatment.
treatment_term:
preferred_term: surgical procedure
term:
id: MAXO:0000004
label: surgical procedure
evidence:
- reference: PMID:32297094
reference_title: "Intracranial growing teratoma syndrome (iGTS): an international case series and review of the literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
All patients underwent surgical resection, leading to gross total resection
in 79%.
explanation: >-
This supports resection as the central management approach for iGTS.
- reference: PMID:32297094
reference_title: "Intracranial growing teratoma syndrome (iGTS): an international case series and review of the literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Complete surgical resection is the mainstay of treatment.
explanation: >-
The conclusion directly identifies complete resection as the iGTS treatment
mainstay.
clinical_trials:
- name: NCT00047320
description: >-
Phase II Children's Oncology Group study of neoadjuvant chemotherapy with or
without second-look surgery, radiotherapy, and high-dose chemotherapy with
peripheral stem cell transplantation for newly diagnosed intracranial
nongerminomatous germ cell tumors.
evidence:
- reference: clinicaltrials:NCT00047320
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
PURPOSE: This Phase II trial is studying how well neoadjuvant chemotherapy
with or without surgery and with or without high dose chemotherapy and
peripheral stem cell transplantation, can increase response rates prior to
radiation therapy and increase progression free and overall surviving
patients with newly diagnosed intracranial germ cell tumors.
explanation: >-
This trial is relevant to mixed or nongerminomatous CNS germ cell tumor
settings that can include immature or teratomatous components.
- name: NCT01424839
description: >-
Prospective SIOP CNS GCT II trial for diagnosis and treatment of children,
adolescents, and young adults with intracranial germ cell tumors, including
teratoma registration and outcome collection.
evidence:
- reference: clinicaltrials:NCT01424839
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
* To register patients and collect data regarding diagnostics, treatment
and outcome in order to develop future treatment strategies
explanation: >-
This trial record explicitly includes teratoma data collection to inform
future treatment strategies.
A CNS teratoma is a rare tumor arising in the brain or spinal axis composed of tissues derived from two or more embryonic germ layers (often all three: ectoderm, mesoderm, endoderm). CNS teratomas are generally categorized into mature teratoma, immature teratoma, and malignant teratoma/teratoma with malignant (somatic-like) transformation, and are part of the broader spectrum of CNS germ cell tumors (GCTs). (zygourakis2015managementofcentral pages 1-2, challa2010teratomasincentral pages 1-2, nowacka2025matureteratomaof pages 5-7)
The evidence used here is primarily aggregated disease-level resources (guidelines, multi-institution cohorts, case series) and some case reports for rare molecular findings and spinal disease presentations. (nakamura2022thejapansociety pages 7-8, takami2023impactoftumor pages 1-2, giron2024primarycentralnervous pages 1-2, zavalaromero2024matureteratomaat pages 1-2)
Embryologic origin hypothesis: CNS GCTs (including teratoma) are widely considered to arise from mismigrated primordial germ cells (PGCs) that become sequestered in midline CNS structures, later undergoing malignant transformation; germinomas and PGCs share global DNA hypomethylation patterns supporting this model. (yeo2023primarycentralnervous pages 1-2, tengattini2024primarycooccurrenceof pages 1-2)
Spinal teratoma hypotheses: spinal teratomas are described with two main theories: (1) dysembryogenic theory (disordered local development with pluripotent cells differentiating chaotically) and (2) misplaced germ cell theory (mis-migration of primordial germ cells from yolk sac to gonad), with some authors considering the misplaced germ cell theory more plausible for adult intraspinal teratomas. (ferdause2023spinalintraduralextramedullary pages 3-3)
Robust environmental risk factors are not established in the extracted evidence. Reported syndromic/germline associations and predispositions include: - Down syndrome, Klinefelter syndrome, and JMJD1C variants reported in CNS GCT literature. (yeo2023primarycentralnervous pages 2-3) - Rare clinical observation of testicular dysgenesis syndrome and Down syndrome among cases with co‑occurring gonadal and CNS GCTs. (tengattini2024primarycooccurrenceof pages 1-2) - A PTEN germline variant has been reported as a pediatric cancer predisposition in the context of intracranial GCT biology (evidence in a recent iGTS case report discussion). (satake2024successfulmultimodaltreatment pages 5-7)
No protective factors or gene–environment interactions specific to CNS teratoma were identified in the retrieved evidence.
CNS teratoma phenotypes are largely driven by tumor location, mass effect, hydrocephalus, and endocrine involvement (suprasellar/hypothalamic–pituitary region). Population-level frequencies are most available for CNS GCT cohorts rather than teratoma-only cohorts.
| Phenotype | Phenotype type | Suggested HPO term | HPO ID | Frequency / count | Typical context / location | Source citation |
|---|---|---|---|---|---|---|
| Headache | Symptom | Headache | HP:0002315 | 24/48 (50.0%) | Common presenting symptom in pediatric CNS GCTs; often associated with pineal/suprasellar mass effect and hydrocephalus | (giron2024primarycentralnervous pages 1-2, giron2024primarycentralnervous pages 2-3) |
| Visual disturbance | Symptom | Abnormality of vision / Visual impairment | HP:0000505 | 17/48 (35.4%) | Frequently reported in suprasellar and pineal region tumors | (giron2024primarycentralnervous pages 1-2, giron2024primarycentralnervous pages 2-3) |
| Vomiting | Symptom | Vomiting | HP:0002013 | 12/48 (25.0%) | Often occurs with raised intracranial pressure or obstructive hydrocephalus | (giron2024primarycentralnervous pages 1-2, giron2024primarycentralnervous pages 2-3) |
| Nausea | Symptom | Nausea | HP:0002018 | 8/48 (16.7%) | Often accompanies increased intracranial pressure | (giron2024primarycentralnervous pages 1-2, giron2024primarycentralnervous pages 2-3) |
| Diabetes insipidus | Endocrine manifestation | Diabetes insipidus | HP:0000873 | 7/48 (14.6%) | Characteristic of suprasellar/hypothalamic-pituitary involvement | (giron2024primarycentralnervous pages 1-2, giron2024primarycentralnervous pages 2-3, yeo2023primarycentralnervous pages 2-3) |
| Precocious puberty | Endocrine manifestation | Precocious puberty | HP:0000826 | 2/48 (4.2%) | Reported in NGGCT patients; may reflect β-hCG secretion | (giron2024primarycentralnervous pages 1-2, giron2024primarycentralnervous pages 2-3) |
| Hydrocephalus | Clinical sign / imaging finding | Hydrocephalus | HP:0000238 | 74/80 | Dominant presenting feature in pediatric pineal region surgical series; especially relevant for pineal tumors | (tomita2023pediatricpinealregion pages 1-2) |
| Parinaud sign / Parinaud syndrome | Clinical sign | Parinaud syndrome | HP:0001108 | 24/80 | Typical of pineal region / dorsal midbrain compression; 16 cases were transient postoperatively in the series | (tomita2023pediatricpinealregion pages 1-2) |
| Hemiparesis | Clinical sign | Hemiparesis | HP:0001269 | 2/80 postoperative transient cases in surgical series; frequency at presentation not fully reported | Can occur with pineal region tumor manipulation or with basal ganglia/thalamic GCTs | (tomita2023pediatricpinealregion pages 1-2, yeo2023primarycentralnervous pages 2-3) |
| Cerebellar ataxia | Clinical sign | Cerebellar ataxia | HP:0001251 | 2/80 postoperative transient cases | Seen as postoperative neurological morbidity in pineal region surgery; cerebellar dysfunction can also occur with posterior fossa/cerebellar lesions | (tomita2023pediatricpinealregion pages 1-2) |
| Hemiballismus | Clinical sign / movement disorder | Hemiballismus | HP:0011446 | 1/80 postoperative transient case | Rare postoperative complication in pineal region tumor surgery | (tomita2023pediatricpinealregion pages 1-2) |
| Bilateral oculomotor palsy | Clinical sign | Oculomotor nerve palsy | HP:0007009 | 1/80 permanent postoperative case | Brainstem / pineal region operative morbidity | (tomita2023pediatricpinealregion pages 1-2) |
| Hemisensory loss | Clinical sign | Hemihypesthesia / Hemisensory loss | not confirmed | 1/80 permanent postoperative case | Reported as permanent deficit after pineal region surgery | (tomita2023pediatricpinealregion pages 1-2) |
| Cranial neuropathy | Clinical sign | Cranial nerve abnormality | HP:0001291 | Frequency not reported | More typical of basal ganglia/thalamic lesions in CNS GCT review | (yeo2023primarycentralnervous pages 2-3) |
| Hemianopia / visual field defect | Clinical sign | Hemianopia | HP:0007343 | 2/80 postoperative cases, transient | Reported after pineal region surgery | (tomita2023pediatricpinealregion pages 1-2) |
| Neurocognitive decline | Behavioral / neurodevelopmental manifestation | Neurocognitive impairment | not confirmed | Frequency not reported | Described particularly with basal ganglia lesions and prolonged disease course | (yeo2023primarycentralnervous pages 2-3) |
Table: This table summarizes common presenting symptoms, neurological signs, and endocrine manifestations relevant to CNS teratoma within the broader CNS germ cell tumor literature. It maps each feature to a suggested HPO term and gives frequencies and anatomical context from recent pediatric series and reviews.
Additional phenotype/location patterns: - Pineal region lesions commonly present with obstructive hydrocephalus and dorsal midbrain signs (Parinaud syndrome). (tomita2023pediatricpinealregion pages 1-2, nowacka2025matureteratomaof pages 5-7) - Suprasellar lesions commonly present with hypothalamic–pituitary dysfunction including diabetes insipidus. (giron2024primarycentralnervous pages 1-2, yeo2023primarycentralnervous pages 2-3) - Basal ganglia/thalamic lesions may present with hemiparesis, cranial neuropathy, and protracted neurocognitive decline. (yeo2023primarycentralnervous pages 2-3)
Quality-of-life impacts: neurologic and endocrine sequelae (e.g., motor/sensory deficits, sphincter dysfunction in spinal disease) can persist and affect long-term function, motivating long-term follow-up. (zavalaromero2024matureteratomaat pages 8-9)
In a large international, histology-verified cohort, AFP was often elevated even without yolk sac tumor, especially in immature teratoma; and HCG elevation was restricted to tumors with germinoma or choriocarcinoma components (with a discernible cut‑off separating those). (takami2023impactoftumor pages 1-2)
A recent intracranial growing teratoma syndrome case with malignant features reported: - DNA methylation classifier confirming teratoma (high calibrated score) - Copy-number alterations including DMRT1 loss and 12p gain; authors discuss DMRT1’s role in primordial germ cells and teratomagenesis evidence from mouse models. (satake2024successfulmultimodaltreatment pages 3-5, satake2024successfulmultimodaltreatment pages 5-7)
Recent reviews highlight developing noninvasive diagnostics for intracranial GCTs using CSF ctDNA, microRNA clusters (miR‑371‑373, miR‑302/367), and methylation profiling, but CNS-specific validation and clinical integration remain ongoing. (yeo2023primarycentralnervous pages 2-3, yeo2025intracranialgermcell pages 3-4)
No specific environmental, lifestyle, toxicologic, or infectious causal factors were identified in the retrieved CNS teratoma-focused evidence.
Intracranial growing teratoma syndrome (iGTS) is defined as paradoxical growth of a (mature) teratoma component during/after therapy for malignant CNS GCT despite normalization of markers; it likely reflects selection/enrichment of mature teratomatous elements not responsive to chemotherapy/radiotherapy and requires surgery. (michaiel2020intracranialgrowingteratoma pages 1-2, nakamura2022thejapansociety pages 5-7)
Suggested ontology terms (examples): - GO biological processes: “cell proliferation”, “germ cell development”, “DNA methylation”, “PI3K signaling”, “MAPK cascade” (IDs not retrieved in this run) - Cell Ontology (CL): “primordial germ cell” (CL term name; ID not retrieved in this run)
Midline structures are typical: - Pineal region, suprasellar region, basal ganglia, thalamus; ventricular involvement may cause hydrocephalus. (zygourakis2015managementofcentral pages 1-2, nowacka2025matureteratomaof pages 5-7)
Suggested UBERON examples (names; IDs not retrieved here): pineal gland, hypothalamus, pituitary gland, spinal cord, conus medullaris.
CNS teratoma is not established as a classic Mendelian inherited disorder in the retrieved evidence. Reported associations (Down, Klinefelter, JMJD1C) are best viewed as predisposition associations within CNS GCT biology rather than a defined inheritance pattern. (yeo2023primarycentralnervous pages 2-3)
AFP can be elevated even without yolk sac tumor histology, particularly in immature teratoma, which complicates marker-only inference of histology. (takami2023impactoftumor pages 1-2)
Definitive diagnosis remains histopathologic identification of germ-layer derivatives; immunohistochemistry supports component identification and differentiation from mixed GCT. (zygourakis2015managementofcentral pages 1-2, nowacka2025matureteratomaof pages 5-7)
Depends on location and imaging; spinal intradural lesions can mimic schwannoma/meningioma; intracranial parenchymal masses may be misdiagnosed as glioma when heterogeneous. (jeong2023adultintramedullarymature pages 1-3)
In the largest extracted multi-institution iGTS series (n=39): - iGTS frequency 5% among 777 CNS GCT - Gross total resection 79% - 95% alive at median follow-up 5.3 years (michaiel2020intracranialgrowingteratoma pages 1-2)
In the AHOPCA cohort (n=48), 5‑year OS 65% overall (germinoma 68%, NGGCT 50.6%), substantially lower than high-income country benchmarks, likely reflecting heterogeneous protocols and incomplete staging resources. (giron2024primarycentralnervous pages 1-2)
Adult spinal teratomas are rare; mature spinal teratomas are reported to have favorable long-term outcomes in reviews (e.g., 10-year survival 92%) with recurrence/regrowth reported (e.g., ~9–11% and regrowth intervals 3–13 years). (zavalaromero2024matureteratomaat pages 8-9)
Treatment is driven by (i) mature vs immature/malignant features, (ii) secretory vs nonsecretory markers, and (iii) localized vs disseminated disease.
| Intervention | Indication (teratoma subtype context) | Evidence summary | Suggested MAXO term (name; ID if unknown mark not confirmed) | Key sources |
|---|---|---|---|---|
| Gross total resection of mature teratoma | Pure mature intracranial or intraspinal teratoma; especially marker-negative localized disease | Surgery is the primary treatment for mature teratoma; guidelines recommend surgery for mature teratomas, and case series/reviews report excellent long-term outcomes after complete resection, with mature teratoma generally not requiring adjuvant radiotherapy if completely resected. Gross total resection is also the mainstay for spinal mature teratoma. (nakamura2022thejapansociety pages 5-7, zavalaromero2024matureteratomaat pages 1-2, zavalaromero2024matureteratomaat pages 8-9, zygourakis2015managementofcentral pages 1-2) | surgical excision of teratoma; MAXO ID not confirmed | (nakamura2022thejapansociety pages 5-7, zavalaromero2024matureteratomaat pages 1-2, zavalaromero2024matureteratomaat pages 8-9, zygourakis2015managementofcentral pages 1-2) |
| Biopsy for suspected germinoma | Midline CNS GCT suspected to be germinoma when markers are negative/equivocal and aggressive resection is not indicated | For suspected germinoma, biopsy rather than aggressive resection is advised to obtain histology. Histopathology remains the standard principle because marker overlap can misclassify NGGCT/teratoma. Endoscopic, stereotactic, transsphenoidal, or open biopsy approaches may be used depending on site. (nakamura2022thejapansociety pages 5-7, nakamura2022thejapansociety pages 4-5, yeo2023primarycentralnervous pages 3-4) | tumor biopsy; MAXO ID not confirmed | (nakamura2022thejapansociety pages 5-7, nakamura2022thejapansociety pages 4-5, yeo2023primarycentralnervous pages 3-4) |
| Endoscopic third ventriculostomy for hydrocephalus | Obstructive hydrocephalus from pineal/suprasellar tumors, including teratoma-containing masses | Hydrocephalus is common in pineal-region disease. ETV is strongly recommended for hydrocephalus associated with CNS GCTs, often combined with biopsy; VPS carries seeding concerns. In a pediatric pineal series, hydrocephalus occurred in 74/80 and was commonly managed before tumor resection. (nakamura2022thejapansociety pages 7-8, tomita2023pediatricpinealregion pages 1-2, yeo2023primarycentralnervous pages 3-4) | endoscopic third ventriculostomy; MAXO ID not confirmed | (nakamura2022thejapansociety pages 7-8, tomita2023pediatricpinealregion pages 1-2, yeo2023primarycentralnervous pages 3-4) |
| Induction platinum-based chemotherapy (carboplatin/etoposide; cisplatin/ifosfamide/etoposide) | Secretory NGGCT; immature teratoma within NGGCT/mixed GCT; residual-risk stratification before surgery/RT | Platinum-etoposide regimens are standard backbones in CNS GCT management. Trials/guidelines use carboplatin+etoposide and cisplatin/ifosfamide/etoposide for induction, particularly for NGGCT; immature teratoma is treated in risk-adapted multimodal protocols rather than surgery alone when part of NGGCT biology. (nakamura2022thejapansociety pages 7-8, NCT00047320 chunk 1, NCT01424839 chunk 2, NCT01424839 chunk 1, takami2023impactoftumor pages 1-2) | platinum-based chemotherapy; MAXO ID not confirmed | (nakamura2022thejapansociety pages 7-8, NCT00047320 chunk 1, NCT01424839 chunk 2, NCT01424839 chunk 1, takami2023impactoftumor pages 1-2) |
| Whole ventricular irradiation | Nondisseminated germinoma after chemotherapy; selected marker-negative/nonsecretory midline CNS GCT pathways | Whole-ventricular irradiation is strongly recommended for nondisseminated germinoma in combination with chemotherapy, with typical doses around 18–24 Gy plus local boost depending on response. This approach is used to reduce long-term toxicity compared with broader fields. (nakamura2022thejapansociety pages 7-8, yeo2023primarycentralnervous pages 3-4, NCT01424839 chunk 2) | whole ventricular irradiation; MAXO ID not confirmed | (nakamura2022thejapansociety pages 7-8, yeo2023primarycentralnervous pages 3-4, NCT01424839 chunk 2) |
| Craniospinal irradiation | Metastatic germinoma/NGGCT; disseminated disease; some high-risk residual or marker-positive protocols | CSI remains standard for metastatic or disseminated CNS GCT and is used in NGGCT protocols and some post-induction regimens. Trials specify CSI with boosts for metastatic germinoma and NGGCT; Satake 2024 used CSI plus boost for aggressive teratomatous disease with malignant features. (NCT00047320 chunk 1, NCT01424839 chunk 2, NCT01424839 chunk 1, satake2024successfulmultimodaltreatment pages 3-5) | craniospinal irradiation; MAXO ID not confirmed | (NCT00047320 chunk 1, NCT01424839 chunk 2, NCT01424839 chunk 1, satake2024successfulmultimodaltreatment pages 3-5) |
| Second-look surgery for residual mass / growing teratoma syndrome | Residual mass after induction therapy; discordant marker/imaging response; suspected GTS; residual NGGCT/immature teratoma | Second-look surgery is recommended for residual primary mass after induction chemotherapy in NGGCT and is specifically useful to diagnose/resect growing teratoma syndrome or viable residual tumor. iGTS occurs in a minority of CNS GCTs and management is primarily surgical, with gross total resection associated with favorable outcomes. (nakamura2022thejapansociety pages 5-7, yeo2023primarycentralnervous pages 3-4, michaiel2020intracranialgrowingteratoma pages 1-2, NCT00047320 chunk 1, NCT01424839 chunk 1) | second-look surgery; MAXO ID not confirmed | (nakamura2022thejapansociety pages 5-7, yeo2023primarycentralnervous pages 3-4, michaiel2020intracranialgrowingteratoma pages 1-2, NCT00047320 chunk 1, NCT01424839 chunk 1) |
| High-dose chemotherapy with autologous stem cell rescue | High-risk NGGCT; suboptimal response after induction/second-look surgery; aggressive teratomatous lesions with malignant features | In ACNS0122, patients with less than partial response after induction/second-look could receive high-dose thiotepa/etoposide with autologous PBSC rescue before radiotherapy. SIOP CNS GCT II includes dose-intensified courses with stem-cell support for high-risk NGGCT. A 2024 pineal iGTS case with malignant features achieved durable remission after surgery, CSI, ICE chemotherapy, and autologous stem-cell transplantation. (NCT00047320 chunk 1, NCT01424839 chunk 2, NCT01424839 chunk 1, satake2024successfulmultimodaltreatment pages 3-5) | autologous hematopoietic stem cell transplantation after high-dose chemotherapy; MAXO ID not confirmed | (NCT00047320 chunk 1, NCT01424839 chunk 2, NCT01424839 chunk 1, satake2024successfulmultimodaltreatment pages 3-5) |
Table: This table summarizes major treatment modalities used in CNS teratoma and related CNS germ cell tumor care, linking each intervention to its clinical context, supporting evidence, and a suggested MAXO term. It is useful for structuring treatment annotations in a disease knowledge base.
No primary prevention strategies are established. Secondary prevention largely consists of timely diagnosis and appropriate staging (MRI brain/spine, CSF cytology, serum/CSF markers) to reduce undertreatment/overtreatment. (yeo2023primarycentralnervous pages 3-4, nakamura2022thejapansociety pages 4-5)
No comparative animal natural disease evidence was identified in the retrieved materials.
Model organism systems were not retrieved in the evidence set for this run. One mechanistic clue referenced in the 2024 iGTS report is that Dmrt1 loss increases teratoma incidence in mouse models, but detailed model descriptions were not extracted here. (satake2024successfulmultimodaltreatment pages 5-7)
| Study (year) | Population/setting | Key CNS teratoma-related findings (include numeric stats, marker thresholds/values, survival) | Notes/limitations | DOI/URL |
|---|---|---|---|---|
| Takami et al. (2023) | International histopathology-verified intracranial GCT cohort; combined n=161 (biopsy n=85, resection n=76), mostly pediatric/adolescent | HCG elevation was limited to tumors with germinoma or choriocarcinoma components; AFP was often elevated without yolk sac tumor, especially in immature teratoma. HCG was elevated only in CSF in 3/52 cases; AFP only in serum in 7/49 cases, supporting testing both serum and CSF. Germinomas comprise ~50–60% of CNS GCTs with >90% long-term survival; NGGCT long-term survival ~60–70%. Immature teratoma had unfavorable prognosis independent of marker status, with 56% 5-year OS. (takami2023impactoftumor pages 1-2, takami2023impactoftumor pages 9-9) | Cohort spans broader CNS GCTs rather than pure teratoma only; marker findings must be interpreted in mixed-histology context. | https://doi.org/10.1007/s10014-023-00460-x |
| Girón et al. (2024) | AHOPCA retrospective pediatric CNS GCT series, 48 patients, 4 countries in Central America/Caribbean, 2001–2021 | Male 31/48 (64.6%); median age 10.2 years. Symptoms: headache 24 (50%), visual disturbance 17 (35.4%), vomiting 12 (25%), nausea 8 (16.7%), diabetes insipidus 7 (14.6%), precocious puberty in 2 NGGCT patients. Sites: suprasellar 17 (35.4%), pineal 13 (27.1%), thalamus/basal ganglia 5 (10.4%), other 12 (25%), bifocal 1. Eight patients were diagnosed/treated from CSF markers alone: 4 germinomas with β-hCG 11.32–29.41 mIU/mL; 4 NGGCT with β-hCG 84.43–201.97 mIU/mL or AFP >10 IU/mL. Metastatic disease in 4/48 (8.3%); positive CSF in 6; 5-year OS 65% overall, 68% germinoma, 50.6% NGGCT, 85.7% unclassified. (giron2024primarycentralnervous pages 1-2, giron2024primarycentralnervous pages 2-3) | Not teratoma-specific; staging incomplete in 52%, treatment heterogeneous, resource-limited setting likely lowered outcomes versus HIC. | https://doi.org/10.3389/fonc.2024.1393454 |
| Tomita et al. (2023) | Single-institution pediatric pineal region tumor surgical series, 80 patients (1990–2019) treated mainly via occipital transtentorial approach | Hydrocephalus in 74/80. Pre-craniotomy CSF diversion: ETV 33, EVD 26, shunt 15; ETV+biopsy in 9. Pathology included 32 germ cell tumors, of which 18 were teratomas. Extent of resection: 55 gross total, 13 subtotal, 10 partial, 2 biopsy; 1 postoperative death. Morbidity mostly transient: hemiparesis 2, cerebellar ataxia 2, hemiballismus 1; permanent hemisensory loss 1 and bilateral oculomotor palsy 1. Parinaud’s sign in 24 patients (16 transient). Figure/Table content from the paper also notes 8 pineal teratomas and 14 NGGCT with teratoma components in the pathology/location summary. (tomita2023pediatricpinealregion pages 1-2, tomita2023pediatricpinealregion media 78dd21ef) | Surgical series of pineal-region tumors, not all teratomas; no teratoma-specific survival or marker values reported in extracted evidence. | https://doi.org/10.1007/s00381-022-05595-4 |
| Michaiel et al. (2020) | International multicenter iGTS series across 22 institutions; 777 CNS GCTs screened, 39 iGTS cases | Intracranial growing teratoma syndrome (iGTS) frequency 5% (39/777). Strong pineal predilection; occurred early, median 2 months from diagnosis. Initial tissue showed immature teratoma in 50% of available cases. Serum AFP or β-hCG detectable in 87% at diagnosis (median AFP 66 ng/mL; median β-hCG 44 IU/L). Gross total resection achieved in 79%; all underwent surgery. At median 5.3-year follow-up, 95% were alive. MRI may show a characteristic “honeycomb” residual mature teratoma appearance. (michaiel2020intracranialgrowingteratoma pages 1-2) | iGTS is a treatment-related syndrome rather than all CNS teratoma; cohort includes mixed malignant GCT precursors. | https://doi.org/10.1007/s11060-020-03486-9 |
| Zygourakis et al. (2015) | Review/case-series perspective on CNS teratoma management | CNS teratomas account for ~0.5–1% of primary adult intracranial tumors, ~7% in children; incidence higher in East Asia (1.8–5% in adults, up to 15% in children). Typical locations are midline intracranial sites; spinal lesions often extramedullary and thoracolumbar. Reported 5-year survival: mature teratoma 87–100%; malignant teratoma 33–71%. Tumor markers (AFP, β-hCG) are part of workup, although one illustrative case had negative serum/CSF markers. (zygourakis2015managementofcentral pages 1-2, zygourakis2015managementofcentral pages 6-7) | Older review; survival ranges come from heterogeneous historical series and mixed pathology definitions. | https://doi.org/10.1016/j.jocn.2014.03.039 |
| Satake et al. (2024) | Single case of pineal mixed GCT evolving into intracranial GTS with malignant features | 14-year-old boy with ~3.3 cm pineal mass and obstructive hydrocephalus. Initial serum AFP 5 ng/mL and β-hCG 6 mIU/mL (negative/low), but CSF PLAP 1280 pg/mL and CSF β-hCG 15 mIU/mL were elevated. During carboplatin/etoposide, serum AFP transiently rose to 81 ng/mL then normalized despite lesion enlargement. Pathology after gross total resection showed teratoma with malignant features; MIB-1 up to 30%. Molecular profiling: methylation classifier teratoma score 0.99; CNV showed DMRT1 loss and 12p gain. Treated with resection, craniospinal irradiation 30.6 Gy + 23.4 Gy boost, six cycles of ICE, and autologous stem-cell transplant; relapse-free for >3 years. (satake2024successfulmultimodaltreatment pages 3-5, satake2024successfulmultimodaltreatment pages 1-3) | Single case report; useful for molecular/pathophysiologic clues but not frequency estimates. | https://doi.org/10.3390/curroncol31040138 |
| Challa et al. (2010) | Clinico-morphological craniospinal teratoma series, 14 cases | Age range birth–57 years (mean ~15.9). Histology: 11/14 mature cystic teratomas, plus single malignant transformation, teratocarcinoma, and mixed germ cell tumor. Distribution: 6 intracranial and 8 spinal. In the authors’ referral series, teratomas comprised <0.1% of intracranial tumors and ~0.6% of spinal tumors. Surgery was primary treatment; adjuvant radiotherapy used for teratocarcinoma and mixed GCT. (challa2010teratomasincentral pages 1-2) | Older, small institutional series; incidence values are center-specific, not population-based. | https://doi.org/10.4103/0028-3886.73740 |
Table: This table summarizes selected quantitative findings from major CNS teratoma and CNS germ cell tumor studies relevant to diagnosis, epidemiology, treatment, and outcomes. It is useful for quickly comparing marker data, survival estimates, and clinical series characteristics across recent and foundational publications.
References
(zygourakis2015managementofcentral pages 1-2): Corinna C. Zygourakis, Jessica L. Davis, Gurvinder Kaur, Christopher P. Ames, Nalin Gupta, Kurtis I. Auguste, and Andrew T. Parsa. Management of central nervous system teratoma. Journal of Clinical Neuroscience, 22:98-104, Jan 2015. URL: https://doi.org/10.1016/j.jocn.2014.03.039, doi:10.1016/j.jocn.2014.03.039. This article has 24 citations and is from a peer-reviewed journal.
(challa2010teratomasincentral pages 1-2): Sundaram Challa, Meetu Agrawal, MeghaS Uppin, MohanaR Patibandla, Suchanda Bhattacharjee, ManasK Panigrahi, Vijay Saradhi, JyotsnaY Rani, and AK Purohit. Teratomas in central nervous system: a clinico-morphological study with review of literature. Neurology India, 58 6:841-6, Nov 2010. URL: https://doi.org/10.4103/0028-3886.73740, doi:10.4103/0028-3886.73740. This article has 61 citations and is from a peer-reviewed journal.
(nowacka2025matureteratomaof pages 5-7): Agnieszka Nowacka, Ewa Ziółkowska, Wojciech Smuczyński, Dominika Bożiłow, and Maciej Śniegocki. Mature teratoma of the cerebellum with formed extracranial component. Journal of Clinical Medicine, 14:1994, Mar 2025. URL: https://doi.org/10.3390/jcm14061994, doi:10.3390/jcm14061994. This article has 0 citations.
(michaiel2020intracranialgrowingteratoma pages 1-2): George Michaiel, Douglas Strother, Nicholas Gottardo, Ute Bartels, Hallie Coltin, Juliette Hukin, Beverly Wilson, Shayna Zelcer, Jordan R. Hansford, Timothy Hassall, Mohamed S. AbdelBaki, Kristina A. Cole, Lindsey Hoffman, Natasha P. Smiley, Amy Smith, Anna Vinitsky, Nicholas A. Vitanza, Avery Wright, Kee K. Yeo, Lionel M. L. Chow, Magimairajan I. Vanan, Girish Dhall, Eric Bouffet, and Lucie Lafay-Cousin. Intracranial growing teratoma syndrome (igts): an international case series and review of the literature. Journal of Neuro-Oncology, 147:721-730, Apr 2020. URL: https://doi.org/10.1007/s11060-020-03486-9, doi:10.1007/s11060-020-03486-9. This article has 41 citations and is from a peer-reviewed journal.
(satake2024successfulmultimodaltreatment pages 1-3): Daiken Satake, Manabu Natsumeda, Kaishi Satomi, Mari Tada, Taro Sato, Noritaka Okubo, Keita Kawabe, Haruhiko Takahashi, Yoshihiro Tsukamoto, Masayasu Okada, Masakazu Sano, Haruko Iwabuchi, Nao Shibata, Masaru Imamura, Chihaya Imai, Hirokazu Takami, Koichi Ichimura, Ryo Nishikawa, Hajime Umezu, Akiyoshi Kakita, and Makoto Oishi. Successful multimodal treatment of intracranial growing teratoma syndrome with malignant features. Current Oncology, 31:1831-1838, Mar 2024. URL: https://doi.org/10.3390/curroncol31040138, doi:10.3390/curroncol31040138. This article has 4 citations.
(nakamura2022thejapansociety pages 7-8): Hideo Nakamura, Hirokazu Takami, Takaaki Yanagisawa, Toshihiro Kumabe, Takamitsu Fujimaki, Yoshiki Arakawa, Katsuyuki Karasawa, Keita Terashima, Hideaki Yokoo, Kohei Fukuoka, Yukihiko Sonoda, Kaori Sakurada, Yohei Mineharu, Toshinori Soejima, Motoaki Fujii, Naoki Shinojima, Junichi Hara, Kai Yamasaki, Junya Fujimura, Fumiyuki Yamasaki, Mayu Takahashi, Tomonari Suzuki, Iori Sato, Ryo Nishikawa, and Kazuhiko Sugiyama. The japan society for neuro-oncology guideline on the diagnosis and treatment of central nervous system germ cell tumors. Neuro-oncology, 24:503-515, Oct 2022. URL: https://doi.org/10.1093/neuonc/noab242, doi:10.1093/neuonc/noab242. This article has 76 citations and is from a domain leading peer-reviewed journal.
(takami2023impactoftumor pages 1-2): Hirokazu Takami, Christopher S. Graffeo, Avital Perry, Caterina Giannini, Yoichi Nakazato, Nobuhito Saito, Masao Matsutani, Ryo Nishikawa, David J. Daniels, and Koichi Ichimura. Impact of tumor markers on diagnosis, treatment and prognosis in cns germ cell tumors: correlations with clinical practice and histopathology. Brain Tumor Pathology, 40:124-132, Mar 2023. URL: https://doi.org/10.1007/s10014-023-00460-x, doi:10.1007/s10014-023-00460-x. This article has 15 citations and is from a peer-reviewed journal.
(giron2024primarycentralnervous pages 1-2): Ana Verónica Girón, Jessica Blanco-Lopez, Patricia Calderon, Reyna Jiron, Estuardo Pineda, Margarita Montero, Yamel Lizardo, Ute Bartels, and Diana S. Osorio. Primary central nervous system germ cell tumors in central america and the caribbean region: an ahopca 20-year experience. Frontiers in Oncology, Jul 2024. URL: https://doi.org/10.3389/fonc.2024.1393454, doi:10.3389/fonc.2024.1393454. This article has 3 citations.
(zavalaromero2024matureteratomaat pages 1-2): Lilian Zavala-Romero, Eliezer Villanueva-Castro, Rudradeep Datta-Banik, Alexis Genaro Ortiz-Altamirano, María Magdalena Rodriguez-Esquivel, Jesús Cienfuegos-Meza, and Juan Nicasio Arriada-Mendicoa. Mature teratoma at the lumbar spinal cord: a case report and literature review. Cureus, Jan 2024. URL: https://doi.org/10.7759/cureus.52307, doi:10.7759/cureus.52307. This article has 3 citations.
(yeo2023primarycentralnervous pages 1-2): Kee Kiat Yeo, Sumanth Nagabushan, Girish Dhall, and Mohamed S. Abdelbaki. Primary central nervous system germ cell tumors in children and young adults: a review of controversies in diagnostic and treatment approach. Neoplasia, 36:100860, Feb 2023. URL: https://doi.org/10.1016/j.neo.2022.100860, doi:10.1016/j.neo.2022.100860. This article has 26 citations and is from a domain leading peer-reviewed journal.
(tengattini2024primarycooccurrenceof pages 1-2): Francesco Tengattini, Cesare Francesco Soffiati, Pier Paolo Panciani, Marco Zeppieri, Tamara Ius, Shahan Momjian, Karl Schaller, Marco Maria Fontanella, and Lucio De Maria. Primary co-occurrence of gonadal and extragonadal central nervous system (cns) germ cell tumors (gcts): case report and review of the literature. Neuroglia, 5:50-62, Mar 2024. URL: https://doi.org/10.3390/neuroglia5010004, doi:10.3390/neuroglia5010004. This article has 1 citations.
(ferdause2023spinalintraduralextramedullary pages 3-3): Jannatul Ferdause, Ariful Islam, Taslima Rahman, Sura Jukrup Momtahena, Zillur Rahman, Tarim Mahmood, and Tasnim Mahmud. Spinal intradural extramedullary mature cystic teratoma at cervical location in an elderly person: a rare case report with review of literature. International Journal on Oncology and Radiotherapy, Apr 2023. URL: https://doi.org/10.51626/ijor.2023.04.00024, doi:10.51626/ijor.2023.04.00024. This article has 1 citations.
(yeo2023primarycentralnervous pages 2-3): Kee Kiat Yeo, Sumanth Nagabushan, Girish Dhall, and Mohamed S. Abdelbaki. Primary central nervous system germ cell tumors in children and young adults: a review of controversies in diagnostic and treatment approach. Neoplasia, 36:100860, Feb 2023. URL: https://doi.org/10.1016/j.neo.2022.100860, doi:10.1016/j.neo.2022.100860. This article has 26 citations and is from a domain leading peer-reviewed journal.
(satake2024successfulmultimodaltreatment pages 5-7): Daiken Satake, Manabu Natsumeda, Kaishi Satomi, Mari Tada, Taro Sato, Noritaka Okubo, Keita Kawabe, Haruhiko Takahashi, Yoshihiro Tsukamoto, Masayasu Okada, Masakazu Sano, Haruko Iwabuchi, Nao Shibata, Masaru Imamura, Chihaya Imai, Hirokazu Takami, Koichi Ichimura, Ryo Nishikawa, Hajime Umezu, Akiyoshi Kakita, and Makoto Oishi. Successful multimodal treatment of intracranial growing teratoma syndrome with malignant features. Current Oncology, 31:1831-1838, Mar 2024. URL: https://doi.org/10.3390/curroncol31040138, doi:10.3390/curroncol31040138. This article has 4 citations.
(giron2024primarycentralnervous pages 2-3): Ana Verónica Girón, Jessica Blanco-Lopez, Patricia Calderon, Reyna Jiron, Estuardo Pineda, Margarita Montero, Yamel Lizardo, Ute Bartels, and Diana S. Osorio. Primary central nervous system germ cell tumors in central america and the caribbean region: an ahopca 20-year experience. Frontiers in Oncology, Jul 2024. URL: https://doi.org/10.3389/fonc.2024.1393454, doi:10.3389/fonc.2024.1393454. This article has 3 citations.
(tomita2023pediatricpinealregion pages 1-2): Tadanori Tomita, Tord D. Alden, and Arthur J. Dipatri. Pediatric pineal region tumors: institutional experience of surgical managements with posterior interhemispheric transtentorial approach. Child's Nervous System, 39:2293-2305, Jul 2023. URL: https://doi.org/10.1007/s00381-022-05595-4, doi:10.1007/s00381-022-05595-4. This article has 22 citations.
(zavalaromero2024matureteratomaat pages 8-9): Lilian Zavala-Romero, Eliezer Villanueva-Castro, Rudradeep Datta-Banik, Alexis Genaro Ortiz-Altamirano, María Magdalena Rodriguez-Esquivel, Jesús Cienfuegos-Meza, and Juan Nicasio Arriada-Mendicoa. Mature teratoma at the lumbar spinal cord: a case report and literature review. Cureus, Jan 2024. URL: https://doi.org/10.7759/cureus.52307, doi:10.7759/cureus.52307. This article has 3 citations.
(yeo2023primarycentralnervous pages 5-6): Kee Kiat Yeo, Sumanth Nagabushan, Girish Dhall, and Mohamed S. Abdelbaki. Primary central nervous system germ cell tumors in children and young adults: a review of controversies in diagnostic and treatment approach. Neoplasia, 36:100860, Feb 2023. URL: https://doi.org/10.1016/j.neo.2022.100860, doi:10.1016/j.neo.2022.100860. This article has 26 citations and is from a domain leading peer-reviewed journal.
(satake2024successfulmultimodaltreatment pages 3-5): Daiken Satake, Manabu Natsumeda, Kaishi Satomi, Mari Tada, Taro Sato, Noritaka Okubo, Keita Kawabe, Haruhiko Takahashi, Yoshihiro Tsukamoto, Masayasu Okada, Masakazu Sano, Haruko Iwabuchi, Nao Shibata, Masaru Imamura, Chihaya Imai, Hirokazu Takami, Koichi Ichimura, Ryo Nishikawa, Hajime Umezu, Akiyoshi Kakita, and Makoto Oishi. Successful multimodal treatment of intracranial growing teratoma syndrome with malignant features. Current Oncology, 31:1831-1838, Mar 2024. URL: https://doi.org/10.3390/curroncol31040138, doi:10.3390/curroncol31040138. This article has 4 citations.
(yeo2025intracranialgermcell pages 3-4): Kee Kiat Yeo, Joanna Gell, Girish Dhall, and Ching Lau. Intracranial germ cell tumors: advancement in genomic diagnostics and the need for novel therapeutics. Frontiers in Oncology, Jan 2025. URL: https://doi.org/10.3389/fonc.2025.1513258, doi:10.3389/fonc.2025.1513258. This article has 1 citations.
(tengattini2024primarycooccurrenceof pages 8-10): Francesco Tengattini, Cesare Francesco Soffiati, Pier Paolo Panciani, Marco Zeppieri, Tamara Ius, Shahan Momjian, Karl Schaller, Marco Maria Fontanella, and Lucio De Maria. Primary co-occurrence of gonadal and extragonadal central nervous system (cns) germ cell tumors (gcts): case report and review of the literature. Neuroglia, 5:50-62, Mar 2024. URL: https://doi.org/10.3390/neuroglia5010004, doi:10.3390/neuroglia5010004. This article has 1 citations.
(yeo2023primarycentralnervous pages 3-4): Kee Kiat Yeo, Sumanth Nagabushan, Girish Dhall, and Mohamed S. Abdelbaki. Primary central nervous system germ cell tumors in children and young adults: a review of controversies in diagnostic and treatment approach. Neoplasia, 36:100860, Feb 2023. URL: https://doi.org/10.1016/j.neo.2022.100860, doi:10.1016/j.neo.2022.100860. This article has 26 citations and is from a domain leading peer-reviewed journal.
(nakamura2022thejapansociety pages 5-7): Hideo Nakamura, Hirokazu Takami, Takaaki Yanagisawa, Toshihiro Kumabe, Takamitsu Fujimaki, Yoshiki Arakawa, Katsuyuki Karasawa, Keita Terashima, Hideaki Yokoo, Kohei Fukuoka, Yukihiko Sonoda, Kaori Sakurada, Yohei Mineharu, Toshinori Soejima, Motoaki Fujii, Naoki Shinojima, Junichi Hara, Kai Yamasaki, Junya Fujimura, Fumiyuki Yamasaki, Mayu Takahashi, Tomonari Suzuki, Iori Sato, Ryo Nishikawa, and Kazuhiko Sugiyama. The japan society for neuro-oncology guideline on the diagnosis and treatment of central nervous system germ cell tumors. Neuro-oncology, 24:503-515, Oct 2022. URL: https://doi.org/10.1093/neuonc/noab242, doi:10.1093/neuonc/noab242. This article has 76 citations and is from a domain leading peer-reviewed journal.
(zavalaromero2024matureteratomaat pages 7-8): Lilian Zavala-Romero, Eliezer Villanueva-Castro, Rudradeep Datta-Banik, Alexis Genaro Ortiz-Altamirano, María Magdalena Rodriguez-Esquivel, Jesús Cienfuegos-Meza, and Juan Nicasio Arriada-Mendicoa. Mature teratoma at the lumbar spinal cord: a case report and literature review. Cureus, Jan 2024. URL: https://doi.org/10.7759/cureus.52307, doi:10.7759/cureus.52307. This article has 3 citations.
(nakamura2022thejapansociety pages 4-5): Hideo Nakamura, Hirokazu Takami, Takaaki Yanagisawa, Toshihiro Kumabe, Takamitsu Fujimaki, Yoshiki Arakawa, Katsuyuki Karasawa, Keita Terashima, Hideaki Yokoo, Kohei Fukuoka, Yukihiko Sonoda, Kaori Sakurada, Yohei Mineharu, Toshinori Soejima, Motoaki Fujii, Naoki Shinojima, Junichi Hara, Kai Yamasaki, Junya Fujimura, Fumiyuki Yamasaki, Mayu Takahashi, Tomonari Suzuki, Iori Sato, Ryo Nishikawa, and Kazuhiko Sugiyama. The japan society for neuro-oncology guideline on the diagnosis and treatment of central nervous system germ cell tumors. Neuro-oncology, 24:503-515, Oct 2022. URL: https://doi.org/10.1093/neuonc/noab242, doi:10.1093/neuonc/noab242. This article has 76 citations and is from a domain leading peer-reviewed journal.
(zhang2025cacaguidelinesfor pages 3-5): Chao Zhang, Xiang Huang, Yijin Gao, Yang Wang, Hongying Ye, Hong Chen, Junping Zhang, Linbo Cai, Chunde Li, Yuqi Zhang, Jingsheng Wang, Songtao Qi, Shuguang Chu, Yuanyuan Huang, Bei Zhang, Zhongping Chen, and Rong Zhang. Caca guidelines for holistic integrative management of central nervous system germ cell tumor. Holistic Integrative Oncology, Jun 2025. URL: https://doi.org/10.1007/s44178-025-00168-2, doi:10.1007/s44178-025-00168-2. This article has 1 citations.
(jeong2023adultintramedullarymature pages 1-3): Sun-Jun Jeong, Jong-Hyeok Park, and Sun-Young Jun. Adult intramedullary mature teratoma of the spinal cord: an unusual case with a review of the literature. The Nerve, 9:161-166, Oct 2023. URL: https://doi.org/10.21129/nerve.2023.00353, doi:10.21129/nerve.2023.00353. This article has 1 citations.
(zygourakis2015managementofcentral pages 6-7): Corinna C. Zygourakis, Jessica L. Davis, Gurvinder Kaur, Christopher P. Ames, Nalin Gupta, Kurtis I. Auguste, and Andrew T. Parsa. Management of central nervous system teratoma. Journal of Clinical Neuroscience, 22:98-104, Jan 2015. URL: https://doi.org/10.1016/j.jocn.2014.03.039, doi:10.1016/j.jocn.2014.03.039. This article has 24 citations and is from a peer-reviewed journal.
(NCT00047320 chunk 1): Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors. Children's Oncology Group. 2004. ClinicalTrials.gov Identifier: NCT00047320
(NCT01424839 chunk 2): Prospective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors. University Hospital Muenster. 2011. ClinicalTrials.gov Identifier: NCT01424839
(NCT01424839 chunk 1): Prospective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors. University Hospital Muenster. 2011. ClinicalTrials.gov Identifier: NCT01424839
(NCT00047320 chunk 2): Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors. Children's Oncology Group. 2004. ClinicalTrials.gov Identifier: NCT00047320
(takami2023impactoftumor pages 9-9): Hirokazu Takami, Christopher S. Graffeo, Avital Perry, Caterina Giannini, Yoichi Nakazato, Nobuhito Saito, Masao Matsutani, Ryo Nishikawa, David J. Daniels, and Koichi Ichimura. Impact of tumor markers on diagnosis, treatment and prognosis in cns germ cell tumors: correlations with clinical practice and histopathology. Brain Tumor Pathology, 40:124-132, Mar 2023. URL: https://doi.org/10.1007/s10014-023-00460-x, doi:10.1007/s10014-023-00460-x. This article has 15 citations and is from a peer-reviewed journal.
(tomita2023pediatricpinealregion media 78dd21ef): Tadanori Tomita, Tord D. Alden, and Arthur J. Dipatri. Pediatric pineal region tumors: institutional experience of surgical managements with posterior interhemispheric transtentorial approach. Child's Nervous System, 39:2293-2305, Jul 2023. URL: https://doi.org/10.1007/s00381-022-05595-4, doi:10.1007/s00381-022-05595-4. This article has 22 citations.